4/A: Neurocrine CCO Corrects Stock Option Exercise Details
Insider Transaction Amendment
Neurocrine Biosciences' Chief Commercial Officer, Eric Benevich, amended a previous filing to correct the number of stock options exercised on November 28, 2025.
Summary
- Eric Benevich, Chief Commercial Officer of Neurocrine Biosciences Inc. (NBIX), filed an amendment (Form 4/A) to correct a previously reported transaction.
- The original Form 4, filed on December 2, 2025, incorrectly stated the exercise of 5,970 stock options.
- The corrected filing indicates that 12,830 stock options were actually exercised on November 28, 2025, at an exercise price of $35.99 per share.
- Following the corrected transaction, Eric Benevich's direct beneficial ownership of Common Stock is 57,723 shares.
- An additional 51,753 shares are reported under indirect beneficial ownership, which is a corrected figure following the November 28, 2025 transactions.
- The exercised options were Incentive Stock Options granted on February 5, 2016, which vested in 48 equal monthly installments starting March 5, 2016, and were due to expire on February 5, 2026.
- The reported beneficial ownership also includes an aggregate of 204 shares purchased on February 28, 2025, and August 29, 2025, through the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The filing is a neutral administrative correction of a previously reported insider transaction, not indicative of new company performance or strategic direction. The underlying transaction (option exercise) is a routine part of executive compensation.
Positives
- The amendment ensures the accuracy of public records regarding insider transactions and beneficial ownership.
- The exercise of stock options by a Chief Commercial Officer indicates the realization of value from their compensation, aligning their interests with shareholders.
Negatives
- An administrative error occurred in the initial filing, requiring a subsequent amendment to correct the reported transaction details.
Risks
- No specific company operational or financial risks were mentioned in this administrative filing.
Future Outlook
This filing is an amendment to a past insider transaction and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This filing is an administrative correction of an insider transaction and does not provide information relevant to broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders: Provides accurate information regarding an executive's beneficial ownership, contributing to market transparency.
- Reporting Person (Eric Benevich): Corrects the public record of his stock option exercise and beneficial holdings.
Key Dates
| Date | Description |
|---|---|
| 02/05/2016 | Date Incentive Stock Option was granted. |
| 03/05/2016 | Date vesting of Incentive Stock Option began (48 equal monthly installments). |
| 02/28/2025 | Date of purchase of shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 08/29/2025 | Date of purchase of shares from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 11/28/2025 | Date of the stock option exercise transaction. |
| 12/02/2025 | Date the original Form 4 was filed. |
| 01/16/2026 | Date the amended Form 4/A was signed by the Attorney-in-Fact. |
| 02/05/2026 | Expiration date of the Incentive Stock Option. |
Keywords
NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, Stock Options, Executive Compensation, Eric Benevich, Amendment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.